Measuring Serum Immune Complexes in Cancer

  1. ROGER D. ROSSEN, M.D.; and
  2. BRIAN C. BARNES, M.D.
  1. The Departments of Microbiology and Immunology, and Internal Medicine, Baylor College of Medicine, and the Veterans Administration Hospital;
    Houston, Texas

    Excerpt

    Circulating tumor antigen-antibody complexes appear to have a role in modulating cell-mediated immune responses against autologous tumors (1, 2). The usual effect is to suppress or block lymphocyte transformation and the generation of tumor-specific cytotoxic lymphocytes (2, 3). New techniques that permit measurement of the low levels of immune complexes in body fluids now make possible testing of the hypothesis that measurement of immune complexes in sera of cancer patients may be useful in detecting the residual tumor, in staging cancer, and in estimating prognosis (4).

    In various human malignant diseases, levels of immune complexes, as measured by the Clq

    This 100-word excerpt has been provided in the absence of an abstract.

    Article and Author Information

    • This work was supported by the Veterans Administration Hospital and National Institutes of Health Grants NCI #20543 and #15333.

    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med April 1, 1978 vol. 88 no. 4 570-571
    1. » Excerpt
    2. Full Text (PDF)
    3. References

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. December 15, 2009, 151 (12)
    1. Alert me to current issues